Vascular protection to increase the safety of tissue plasminogen activator for stroke

Tauheed Ishrat, Sahar Soliman, Weihua Guan, Mihaela Saler, Susan C. Fagan

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.

Original languageEnglish (US)
Pages (from-to)3677-3684
Number of pages8
JournalCurrent Pharmaceutical Design
Volume18
Issue number25
DOIs
StatePublished - Oct 22 2012

Fingerprint

Tissue Plasminogen Activator
Blood Vessels
Stroke
Safety
Protective Agents
Thrombolytic Therapy
Edema
Therapeutics
Pharmacology

Keywords

  • Blood-brain barrier
  • Hemorrhagic transformation (HT)
  • Ischemic stroke
  • Matrix metalloproteinases (MMPs)
  • Thrombolysis
  • Tissue plasminogen activator (tPA)
  • Vascular protection

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

Vascular protection to increase the safety of tissue plasminogen activator for stroke. / Ishrat, Tauheed; Soliman, Sahar; Guan, Weihua; Saler, Mihaela; Fagan, Susan C.

In: Current Pharmaceutical Design, Vol. 18, No. 25, 22.10.2012, p. 3677-3684.

Research output: Contribution to journalReview article

Ishrat, Tauheed ; Soliman, Sahar ; Guan, Weihua ; Saler, Mihaela ; Fagan, Susan C. / Vascular protection to increase the safety of tissue plasminogen activator for stroke. In: Current Pharmaceutical Design. 2012 ; Vol. 18, No. 25. pp. 3677-3684.
@article{1d3cbc9216584362bd6afe6c8dbc97bf,
title = "Vascular protection to increase the safety of tissue plasminogen activator for stroke",
abstract = "Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.",
keywords = "Blood-brain barrier, Hemorrhagic transformation (HT), Ischemic stroke, Matrix metalloproteinases (MMPs), Thrombolysis, Tissue plasminogen activator (tPA), Vascular protection",
author = "Tauheed Ishrat and Sahar Soliman and Weihua Guan and Mihaela Saler and Fagan, {Susan C.}",
year = "2012",
month = "10",
day = "22",
doi = "10.2174/138161212802002779",
language = "English (US)",
volume = "18",
pages = "3677--3684",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "25",

}

TY - JOUR

T1 - Vascular protection to increase the safety of tissue plasminogen activator for stroke

AU - Ishrat, Tauheed

AU - Soliman, Sahar

AU - Guan, Weihua

AU - Saler, Mihaela

AU - Fagan, Susan C.

PY - 2012/10/22

Y1 - 2012/10/22

N2 - Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.

AB - Thrombolytic therapy with tissue plasminogen activator (tPA) remains the most effective treatment for acute ischemic stroke, but can cause vascular damage leading to edema formation and hemorrhagic transformation (HT). In this review, we discuss how tPA contributes to the pathogenesis of vascular damage and highlight evidence to support combination therapy of tPA with pharmacological agents that are vascular protective. There is an unmet need to develop therapeutic interventions which target the underlying mechanisms of vascular damage after acute ischemic stroke in order to prevent HT and improve the safety and impact of tPA.

KW - Blood-brain barrier

KW - Hemorrhagic transformation (HT)

KW - Ischemic stroke

KW - Matrix metalloproteinases (MMPs)

KW - Thrombolysis

KW - Tissue plasminogen activator (tPA)

KW - Vascular protection

UR - http://www.scopus.com/inward/record.url?scp=84867563380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867563380&partnerID=8YFLogxK

U2 - 10.2174/138161212802002779

DO - 10.2174/138161212802002779

M3 - Review article

VL - 18

SP - 3677

EP - 3684

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 25

ER -